Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | PYGL | P06737 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628354 | 1.00 | HDAC8 (0.60) | HDAC8HDAC1HDAC6PYGLMEN1 | |
| SCHEMBL4627652 | 0.89 | HDAC8 (0.56) | HDAC8HDAC1HDAC6PYGLMEN1 | |
| SCHEMBL4627655 | 0.89 | HDAC8 (0.56) | HDAC8HDAC1HDAC6PYGLMEN1 | |
| SCHEMBL4627898 | 0.82 | HDAC1 (0.54) | HDAC8HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL4627896 | 0.82 | HDAC1 (0.54) | HDAC8HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL8320922 | 0.77 | MEN1 (0.55) | PYGLMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6066354 | 0.76 | MEN1 (0.59) | HDAC8HDAC1HDAC6PYGLMEN1 | |
| SCHEMBL13425267 | 0.75 | MAPT (0.52) | HDAC8HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL4627827 | 0.75 | PYGL (0.57) | HDAC8HDAC1HDAC6PYGLMEN1 | |
| SCHEMBL15808412 | 0.73 | CYP2C9 (0.49) | HDAC8HDAC1HDAC6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590333-A4 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS INC (KR) | 2008-04-30 | — | — | EP | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
| EP-1590333-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Crystalgenomics, Inc. (KR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065370-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS, INC. (KR) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | GSK3B, GSK3A, GYS2 | HDAC8 1233/4885HDAC1 1451/4885HDAC6 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.